Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Department of Oral Medicine and Pathology, Institute of Odontology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Department of Medical Sciences Hematology, Uppsala University, Uppsala, Sweden.
Show others and affiliations
2022 (English)In: Bone Marrow Transplantation, ISSN 0268-3369, E-ISSN 1476-5365, Vol. 57, no 2, p. 191-197Article in journal (Refereed) Published
Abstract [en]

Cryoprevention (CP) using ice (IC) is an effective strategy to prevent chemotherapy-induced oral mucositis (OM). However, the use of IC may cause adverse reactions and requires water of safe quality to minimize risk of serious infections. This randomized, blinded, parallel group, phase 3 trial was conducted in five Scandinavian centers. Eligible patients were diagnosed with multiple myeloma or lymphoma, scheduled to receive conditioning with high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation (ASCT). Patients were assigned to cooling with IC or a novel intraoral cooling device (ICD). The primary outcome was the highest OM score during the study period, expressed as peak value on the Oral Mucositis Assessment Scale (OMAS–total). When the entire study population (n = 172) was analyzed for peak OMAS–total, the two cooling methods were equally effective. However, when the lymphoma group was analyzed separately, the ICD significantly reduced the peak OMAS–total score to a greater extent compared to IC (x̄ ± SD; 1.77 ± 1.59 vs. 3.08 ± 1.50; p = 0.047). Combined with existing evidence, the results of the present trial confirm that CP is an effective method to prevent OM.

ClinicalTrials.gov. NCT03203733.

Place, publisher, year, edition, pages
Springer Nature, 2022. Vol. 57, no 2, p. 191-197
National Category
Hematology
Identifiers
URN: urn:nbn:se:umu:diva-189557DOI: 10.1038/s41409-021-01512-6ISI: 000713942300001PubMedID: 34728786Scopus ID: 2-s2.0-85118421846OAI: oai:DiVA.org:umu-189557DiVA, id: diva2:1611738
Funder
Vinnova, 2016-04171Available from: 2021-11-16 Created: 2021-11-16 Last updated: 2022-07-12Bibliographically approved

Open Access in DiVA

fulltext(1015 kB)150 downloads
File information
File name FULLTEXT02.pdfFile size 1015 kBChecksum SHA-512
a3f059f19741bbcf4df0c88a6ca616e62d243e37941e670f2a3e6ae3e955f9c89e91f721bd04606a885e3a9752ff8956077c2422e698dece9a8c712024c30f58
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Henriksson, RogerTavelin, Björn

Search in DiVA

By author/editor
Henriksson, RogerTavelin, Björn
By organisation
Oncology
In the same journal
Bone Marrow Transplantation
Hematology

Search outside of DiVA

GoogleGoogle Scholar
Total: 183 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 265 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf